Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.32 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1230929 | 0.81 | DYRK1A (0.43) | ALDH1A1KMT2ATLR7 | |
| SCHEMBL1233066 | 0.80 | KMT2A (0.42) | ALDH1A1KMT2AP2RX3 | |
| SCHEMBL1233520 | 0.78 | ALDH1A1 (0.38) | ALDH1A1KMT2ATLR7P2RX3 | |
| SCHEMBL5124491 | 0.75 | MEN1 (0.33) | ALDH1A1KMT2ATLR7 | |
| SCHEMBL4792944 | 0.75 | HPGD (0.40) | ALDH1A1KMT2ATLR7 | |
| SCHEMBL4792366 | 0.74 | HPGD (0.39) | KMT2ATLR7 | |
| SCHEMBL1490737 | 0.74 | TLR7 (0.51) | TLR7 | |
| SCHEMBL4794750 | 0.73 | HPGD (0.39) | KMT2ATLR7 | |
| SCHEMBL4792078 | 0.73 | HPGD (0.39) | KMT2ATLR7 | |
| SCHEMBL6096040 | 0.72 | TLR7 (0.43) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888349-B2 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | IL4, IL2, IL5 | ALDH1A1 401/4885KMT2A 2219/4885TLR7 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.